Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹311 Cr revenue.
COGS 28.4%, employees 20.1%.
“revenue grew by 12% in q three”
“profitability improved sharply with batch up”
“Poultry margins upwards of 20% consistently for last four quarters”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.1%▲ | 10.5% |
| ROCE | 11.3%▼ | 13.8% |
| Net Margin | 12.8%▲ | 8.7% |
| EBITDA Margin | 24.1%▲ | 16.0% |
| Debt To Equity | 0.61x▲ | 0.21x |
| Rev Growth 3yr | 8.2%▲ | 5.8% |
| EPS Growth 3yr | -11.3%▼ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹314 Cr +1.1% | ₹311 Cr +2.2% | ₹305 Cr +14.5% | ₹266 Cr +13.2% | ₹235 Cr +9.6% | ₹214 Cr +16.9% | ₹183 Cr +2.9% | ₹178 Cr |
| Other Income | ₹6 Cr +46.8% | ₹4 Cr -63.1% | ₹11 Cr -29.8% | ₹15 Cr +10.3% | ₹14 Cr +193.4% | ₹5 Cr -26.4% | ₹6 Cr -11.7% | ₹7 Cr |
| Total Income | ₹320 Cr +1.6% | ₹315 Cr -0.1% | ₹315 Cr +12.1% | ₹281 Cr +13.1% | ₹249 Cr +13.6% | ₹219 Cr +15.5% | ₹190 Cr +2.4% | ₹185 Cr |
| COGS | ₹83 Cr -5.7% | ₹88 Cr -7.9% | ₹96 Cr +23.7% | ₹77 Cr +23.6% | ₹63 Cr +24.9% | ₹50 Cr +154.8% | ₹20 Cr -31.8% | ₹29 Cr |
| ₹272 Cr -2.9% | ₹280 Cr -2.9% | ₹288 Cr +17.2% | ₹245 Cr +25.5% | ₹196 Cr +18.2% | ₹166 Cr +11.7% | ₹148 Cr +15.5% | ₹128 Cr | |
| Profit Before Tax | ₹49 Cr +37.2% | ₹35 Cr +29.7% | ₹27 Cr -23.5% | ₹36 Cr -32.7% | ₹53 Cr +5.9% | ₹50 Cr +21.2% | ₹41 Cr -27.3% | ₹57 Cr |
| ₹12 Cr +11.8% | ₹11 Cr -0.4% | ₹11 Cr -11.0% | ₹12 Cr -13.5% | ₹14 Cr -9.0% | ₹15 Cr +49.2% | ₹10 Cr -36.1% | ₹16 Cr | |
| Net Profit | ₹42 Cr +47.4% | ₹29 Cr +36.2% | ₹21 Cr -24.5% | ₹28 Cr -29.0% | ₹39 Cr +13.8% | ₹35 Cr +11.9% | ₹31 Cr -23.8% | ₹41 Cr |
| Profit (Owners) | ₹41 Cr +49.0% | ₹27 Cr +45.5% | ₹19 Cr -29.1% | ₹27 Cr -32.3% | ₹39 Cr +14.2% | ₹34 Cr +18.0% | ₹29 Cr -29.8% | ₹42 Cr |
| Minority Interest | ₹2 Cr +14.4% | ₹1 Cr -41.2% | ₹2 Cr +61.7% | ₹1 Cr +758.5% | ₹0.16 Cr -38.8% | ₹0.27 Cr -85.4% | ₹2 Cr ↑ Recovery | (₹0.87 Cr) |
| Other Comprehensive Income | (₹2 Cr) ↓ Decline | ₹0.06 Cr ↑ Recovery | (₹0.03 Cr) ↓ Decline | ₹2 Cr +97.9% | ₹0.82 Cr ↑ Recovery | (₹2 Cr) ↓ Decline | ₹2 Cr ↑ Recovery | (₹0.25 Cr) |
| EPS | ₹48.14 | ₹32.31 | ₹22.20 | ₹31.30 | ₹46.22 | ₹40.47 | ₹34.29 | ₹48.86 |
| Diluted Shares | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr |
| Profit Or Loss Of Associates | ₹6 Cr +42.1% | ₹4 Cr -11.0% | ₹5 Cr +4.5% | ₹4 Cr +942.3% | ₹0.42 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Hester Biosciences Limited has informed the Exchange about General Updates - Announcement under Regulation 30 of Listing Regulations - Disclosure on amendments in loan agreement of Hester Africa
Hester Biosciences Limited has informed the Exchange about General Updates
Hester Biosciences Limited has informed the Exchange about Transcript
Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
Hester Biosciences Limited has informed the Exchange about Link of Recording
Hester Biosciences Limited has informed the Exchange about General Updates
Hester Biosciences Limited has informed the Exchange about Intimation of receipt of request for Reclassification from the Promoters to the Public category in accordance with Regulation 31A of SEBI...
Hester Biosciences Limited has informed the Exchange regarding Appointment of Ms. Priya Gandhi as Executive Director of the company w.e.f. October 28, 2026.
Hester Biosciences Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "20250515 Press Release Q4 & FY26".
Hester Biosciences Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2026, recommended Final Dividend of Rs. 11 per equity share.
Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Hester Biosciences Limited has informed the Exchange about Schedule of meet
Hester Biosciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Reg...
Hester Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Hester Biosciences Limited has informed the Exchange about Credit Rating